NasdaqGS:QDEL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Quidel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QDEL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: QDEL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

10.1%

QDEL

2.0%

US Medical Equipment

0.7%

US Market


1 Year Return

190.9%

QDEL

19.1%

US Medical Equipment

22.2%

US Market

Return vs Industry: QDEL exceeded the US Medical Equipment industry which returned 19.4% over the past year.

Return vs Market: QDEL exceeded the US Market which returned 22.7% over the past year.


Shareholder returns

QDELIndustryMarket
7 Day10.1%2.0%0.7%
30 Day-19.9%5.6%11.8%
90 Day25.8%6.3%8.6%
1 Year190.9%190.9%20.1%19.1%25.0%22.2%
3 Year400.0%400.0%75.3%70.8%49.4%39.5%
5 Year813.6%813.6%143.2%124.6%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is Quidel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quidel undervalued compared to its fair value and its price relative to the market?

22.56x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: QDEL ($198.98) is trading above our estimate of fair value ($96.33)

Significantly Below Fair Value: QDEL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: QDEL is good value based on its PE Ratio (22.6x) compared to the US Medical Equipment industry average (48.9x).

PE vs Market: QDEL is poor value based on its PE Ratio (22.6x) compared to the US market (19.4x).


Price to Earnings Growth Ratio

PEG Ratio: QDEL is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: QDEL is overvalued based on its PB Ratio (9.8x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Quidel forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

22.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QDEL's forecast earnings growth (22.3% per year) is above the savings rate (2.2%).

Earnings vs Market: QDEL's earnings (22.3% per year) are forecast to grow faster than the US market (21.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: QDEL's revenue (13% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: QDEL's revenue (13% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QDEL's Return on Equity is forecast to be high in 3 years time (33%)


Next Steps

Past Performance

How has Quidel performed over the past 5 years?

79.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QDEL has a high level of non-cash earnings.

Growing Profit Margin: QDEL's current net profit margins (36.9%) are higher than last year (14.5%).


Past Earnings Growth Analysis

Earnings Trend: QDEL's earnings have grown significantly by 79% per year over the past 5 years.

Accelerating Growth: QDEL's earnings growth over the past year (396%) exceeds its 5-year average (79% per year).

Earnings vs Industry: QDEL earnings growth over the past year (396%) exceeded the Medical Equipment industry 0.2%.


Return on Equity

High ROE: QDEL's Return on Equity (43.7%) is considered outstanding.


Next Steps

Financial Health

How is Quidel's financial position?


Financial Position Analysis

Short Term Liabilities: QDEL's short term assets ($560.9M) exceed its short term liabilities ($207.9M).

Long Term Liabilities: QDEL's short term assets ($560.9M) exceed its long term liabilities ($192.2M).


Debt to Equity History and Analysis

Debt Level: QDEL's debt to equity ratio (0.8%) is considered satisfactory.

Reducing Debt: QDEL's debt to equity ratio has reduced from 64.7% to 0.8% over the past 5 years.

Debt Coverage: QDEL's debt is well covered by operating cash flow (3559.7%).

Interest Coverage: QDEL's interest payments on its debt are well covered by EBIT (51x coverage).


Balance Sheet


Next Steps

Dividend

What is Quidel current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QDEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QDEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QDEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QDEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QDEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Doug Bryant (62 yo)

11.75yrs

Tenure

US$4,168,766

Compensation

Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice Presid...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD4.17M) is below average for companies of similar size in the US market ($USD6.94M).

Compensation vs Earnings: Doug's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Bryant
President11.75yrsUS$4.17m1.08%
$ 90.7m
Randall Steward
Chief Financial Officer9.17yrsUS$1.58m0.0080%
$ 670.5k
Robert Bujarski
Chief Operating Officer0.25yrUS$1.39m0.033%
$ 2.8m
Ratan Borkar
Senior Vice President of International Commercial Operations3.17yrsUS$1.37m0.0013%
$ 104.6k
Werner Kroll
Senior Vice President of Research & Development6.58yrsUS$1.23m0.011%
$ 914.9k
Ruben Argueta
Director of Investor Relationsno datano datano data
Michael Abney
Senior Vice President of North American Sales & Distribution5.92yrsUS$1.49m0.016%
$ 1.3m
Edward Russell
Senior Vice President of Business Development5.17yrsUS$1.11m0.041%
$ 3.4m
Karen Gibson
Senior Vice President of Information Systems & Business Transformation1.83yrsno data0.0028%
$ 237.7k
William Ferenczy
Senior Vice President of Cardiometabolic Business Unit0.92yrno data0.010%
$ 873.9k
Tamara Ranalli
Senior Vice President of Molecular Business Unit0.33yrno data0.021%
$ 1.8m
Phillip Askim
Secretaryno datano datano data

4.2yrs

Average Tenure

58yo

Average Age

Experienced Management: QDEL's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Douglas Bryant
President11.75yrsUS$4.17m1.08%
$ 90.7m
Ann Rhoads
Director0.33yrno datano data
Kenneth Widder
Independent Director6.08yrsUS$197.95k0.034%
$ 2.9m
Kenneth Buechler
Independent Chairman5.33yrsUS$240.06k0.14%
$ 12.0m
Edward Michael
Independent Director2yrsUS$204.43k0.015%
$ 1.3m
Charles Slacik
Independent Director5.08yrsUS$196.92k0.027%
$ 2.2m
Mary Polan
Independent Director27.83yrsUS$184.92k0.084%
$ 7.0m
Kathy Ordonez
Independent Director1.5yrsUS$155.82k0.0044%
$ 369.1k
Matthew Strobeck
Independent Director2.67yrsUS$184.92k0.057%
$ 4.8m

5.1yrs

Average Tenure

66yo

Average Age

Experienced Board: QDEL's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QDEL insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Quidel Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quidel Corporation
  • Ticker: QDEL
  • Exchange: NasdaqGS
  • Founded: 1979
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$8.371b
  • Shares outstanding: 42.07m
  • Website: https://www.quidel.com

Number of Employees


Location

  • Quidel Corporation
  • 9975 Summers Ridge Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QDELNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1983
QL1DB (Deutsche Boerse AG)YesCommon StockDEEUROct 1983
QBSWOTCBB (OTC Bulletin Board)YesCommon StockUSUSDOct 1983
0A55LSE (London Stock Exchange)YesCommon StockGBUSDOct 1983

Biography

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal di...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:23
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.